欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
目的探讨经皮冠状动脉介入（PCI）围术期静脉水化预防早期对比剂。肾损害的意义。方法纳入322例行PCI治疗的患者，匹配一般资料后，随机人组静脉水化组154例和对照组168例。静脉水化组患者在术前6h至术后24h按1．0—1．5mL／（h·kg）给予等渗生理盐水持续静脉滴注。未行水化者为对照组。所有人组患者术前24h及术后48—72h分别检测血中超敏C一反应蛋白（Hs—CRP）、B2一微球蛋白（[32一MG）、血肌酐（scr）、血清胱抑素C（Cys—C）水平，分析比较2组对比剂肾病（CIN）的发生率及术前、术后相关指标的变化。结果静脉水化组CIN发生率3．9％明显低于对照组的15．5％（P〈0．05）；对照组术后血Hs—CRP、[32一MG、Cys—C上升，明显高于静脉水化组，2组比较差异有统计学意义（P〈0．01）。结论PCI围术期静脉充分水化可有效预防早期CIN的m珊．
英文摘要：
Objective To observe the clinical effect of early hemofihration combined hemoperfusion （HF/HP） therapy in se- vere acute pancreatitis （SAP）. Methods 82 patients diagnosed as SAP in our hospital were recruited. Retrospective analyzed their clinical data and analyzed. In addition to traditional treatment, all patients accepted HF/HP therapy. Results All 82 patients well toler- ated HF/HP therapy, 67 of them with clinical symptom obviously relieved. Acute physiology and chronic health （APACHE -II） score were significantly decreased （ P 〈 0.05 ）. The total effective rate was 81.7%. Conclusion Individualized comprehensive treatment combined with early HF/HP may significantly reduce the mortality of SAP.
同期刊论文项目
同项目期刊论文
期刊信息
位置：